Guangming Daily, Beijing, November 27th, by reporter Bei DongIt is learned from the National Medical Insurance Administration that the centralized procurement of drugs organized by the special state of insulin was opened in Shanghai on November 26, and the results of the proposed selection were produced. The average price of the selected products was reduced by 48%, which is expected to save 9 billion yuan each year.
According to reports, this collection covers the second- and third-generation insulins commonly used in clinical practice, including 16 common name varieties. The purchase demand of medical institutions nationwide in the first year was about 210 million. Based on the pre-collection price, the purchase amount involved was about 17 billion yuan.
Insulin is an important drug for diabetic patients to control blood sugar, and it has an irreplaceable position in the treatment of diabetes. Because insulin needs to be used for a long time, the excessively high price brings a heavy burden to patients. All domestic and foreign enterprises in this centralized procurement have their products selected. The products to be selected include both well-known enterprise products commonly used by medical institutions and emerging enterprise products. While reducing the falsely high prices, they have achieved a higher match with actual clinical needs. Spend. “Take insulin glargine, which is commonly used in clinical practice, as an example. From an average of 180 yuan per tube to about 70 yuan per tube, each patient can save about 4,000 yuan per year.” The relevant person in charge of the National Medical Insurance Bureau told reporters.
It is understood that this centralized procurement adheres to the “integration of recruitment and procurement, linked to volume and price”, and on the basis of the successful experience in the early exploration of centralized procurement of drugs and consumables, the procurement rules have been optimized for the characteristics of insulin. The first is to fully respect clinical choices, maintain the stability of clinical medications, and reduce the risk of substitution; the second is the combined competition of different generic names of insulin with the same therapeutic purpose and clinical action mechanism, taking into account the needs of clinical use and the adequacy of competition; the third is to attach great importance to the selection For product supply, in accordance with the characteristics of insulin production and use, multiple measures will be taken to ensure the supply through the bottom-line survey of production capacity and sufficient production preparation time.
“This special insulin procurement is the first time that the state organizes centralized drug procurement to expand into the field of biological drugs. It is an important milestone in the process of centralized procurement reform. It not only promotes the return of insulin prices to a reasonable level and benefits more patients, but also contributes to the improvement of the centralized procurement system and the realization of The reform goal is also of great significance.” The relevant person in charge of the National Medical Insurance Bureau said.Return to Sohu to see more
Editor:
Disclaimer: The opinions of this article only represent the author himself. Sohu is an information publishing platform. Sohu only provides information storage space services.
.